Spruce Biosciences Financials - Benzinga

Spruce Biosciences Inc

SPRBNASDAQ

Trade with Public

Trade with Public

$53.05

-0.81-1.5%

At close: Sep 18, 5:00 PM EST

$53.05

N/A

After Hours: Sep 18, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Spruce Biosciences Financials

Spruce Biosciences (SPRB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) Estimate

SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(6.68) per share which missed the analyst consensus estimate of $(5.80) by 15.17 percent. This is a 90.86 percent decrease over

Benzinga Newsdesk

PRO
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q1 EPS $(8.94) Misses $(8.78) Estimate

SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(8.94) per share which missed the analyst consensus estimate of $(8.78) by 1.82 percent. This is a 62.75 percent increase over

Benzinga Newsdesk

Stock Market Today: Dow Jones, S&P 500 Futures Edge Higher With Eyes On Iran Talks—Apple, UnitedHealth, 3M In Focus (UPDATED)

(Editor’s note: The futures and ETFs data were updated.) U.S. stock futures rose on Tuesday following Monday's decline. Futures of major benchmark indices edged up, with negotiating teams from the United States and Iran slated to arrive in Islamabad for further talks.

Benzinga Neuro

PRO
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q4 EPS $(36.25) Misses $(4.22) Estimate

SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(36.25) per share which missed the analyst consensus estimate of $(4.22) by 757.99 percent. This is a 15.2 percent increase over

Benzinga Newsdesk

PRO
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q3 EPS $(14.58) Misses $(13.94) Estimate

SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(14.58) per share which missed the analyst consensus estimate of $(13.94) by 4.63 percent. This is a 7.43 percent increase over

Benzinga Newsdesk

PRO
Spruce Biosciences Q2 EPS $(3.50) Beats $(19.13) Estimate

Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(3.50) per share which beat the analyst consensus estimate of $(19.13) by 81.7 percent. This is a 1490.91 percent decrease over losses of $(0.22) per share

Benzinga Newsdesk